
æ°åã³ãããŠã€ã«ã¹ã®å¶éã«ããæ°å人ãããã§æ»äº¡ããããšãæ°ããªç ç©¶ã§æããã«
å èšäºã¯ãã¡ããã/Click here to read the original article.
6æ1æ¥æææ¥ã«çºè¡šãããå€§èŠæš¡ãªåœéç ç©¶ã§ã¯ãCovidãã³ãããã¯ã®æåã®9ãµæéã«ã髿åŸåœ7ãµåœã§äºæ³ããã55,000äŸã®ããçäŸã蚺æãããªãã£ãããšãæããã«ãªã£ããåç ç©¶ã¯ã2020幎ã«Covidãæžå¿µãããäžã§ãã¹ã¯ãªãŒãã³ã°ã®äžæ¢ãå»åž«ãžã®ã¢ã¯ã»ã¹ã®æžå°ãããã³äžè¬åžæ°ãå»ççŸå Žã«å ¥ãããšã«æ¶æ¥µçã«ãªã£ãããšã«ããé ããè²»çšã«ã€ããŠããããŸã§ã§æãæç¢ºãªå°ºåºŠã®1ã€ãæäŸããŠããããã®äžæã«ããããé¢é£æ»ã®è¶ éæ°ã17,390äººãšæšå®ããã2026幎ã®å¥ã®ç ç©¶ãšãšãã«ããããã®æ°ããªç¥èŠã¯ã6幎åã«ç ç²ã«ãªã£ããã®ã®èŠæš¡ãå ¬åŒã«å£éèŠãããšãã§ããã
2026幎6æ1æ¥ã«Lancet Oncologyèªã«çºè¡šãããåç ç©¶ã§ã¯ããªãŒã¹ãã©ãªã¢ãã«ããããã³ããŒã¯ãã¢ã€ã«ã©ã³ãããã¥ãŒãžãŒã©ã³ãããã«ãŠã§ãŒããã³è±åœã®18管èœåºåã®ããæ£è 260äžäººã®ããŒã¿ã調æ»ããããç ç©¶è ãã¯ã2020幎4æïœ12æã«èгå¯ããããã蚺æãšã2015ïœ2019幎ã®ãã³ãããã¯åã®åŸåã«åºã¥ãäºæž¬èšºæãæ¯èŒãããäºæž¬çäŸ347,666äŸã®ãã¡ã55,713äŸãèŠéãããŠãããšäºæž¬ãããããã¯äºæž¬çäŸã®16%ã«çžåœããã
ãããã®èŠéããã蚺æã¯ãããã®çš®é¡éã§åçã«ååžããŠããªãã£ããæã倧ããªæ¬ é¥ã¯ãåç«è ºããã女æ§ä¹³ãããããã³é»è²è «ã§çºèŠãããããããã¯ãã¹ãŠãã¹ã¯ãªãŒãã³ã°ããã©ã€ããªã±ã¢ãžã®ã¢ã¯ã»ã¹ãããã³æ©æèª¿æ»ãæ€åºã«ãããŠäž»èŠãªåœ¹å²ãæããããšãã§ããæ¡ä»¶ã§ãããèºçããã³åµå·£çã¯åœ±é¿ãåãã«ããã£ãããããã¯ããããå€ãã®çäŸãã«ãŒãã³ã®ã¹ã¯ãªãŒãã³ã°ãããçåæ§ãŸãã¯ç·æ¥ã®çµè·¯ãéããŠèšºæãããããã§ãããã
èŠåºãã®æ°åãæããã«ããã®ã¯:
55,713人ã®äºæ³ãããããçäŸãèŠéãããŠãããšäºæž¬ããã
2020幎4æãã12æã®éã«äºæ³ããã蚺æã®16%ãååšããªãã£ã
åç«è ºããã®èšºæã¯äºæ³ã¬ãã«ãšæ¯èŒããŠ24%æžå°ãã
女æ§ã®ä¹³ããã®èšºæã¯18%æžå°ãã
ã¡ã©ããŒãã®èšºæã¯18%æžå°ãã
åµå·£ããã®èšºæã¯4%æžå°ãã
èºããã¯8%æžå°ãã
ãã¡ããã2020幎ã«ãããäžæçã«æžå°ããããã§ã¯ãªãã£ãããããã®æ°åã¯ãCovidãã³ãããã¯å¯Ÿçããå»çæŽå©ãæ±ããããšãæãã人ã ã«äžããæ·±å»ãªåœ±é¿ã衚ããŠãããã¹ã¯ãªãŒãã³ã°ããã°ã©ã ã¯äžæ¢ããããã©ã€ããªã±ã¢ã®äºçŽãžã®ã¢ã¯ã»ã¹ãå°é£ã«ãªããç é¢ã¯Covidãäžå¿ã«åç·šæãããå€ãã®æ£è ã¯ææã®æãã®ããã«å»çæœèšãé¿ããã
International Cancer Benchmarking Partnershipãšå ±ã«åç ç©¶ã«åãçµãã International Agency for Research on Cancerã¯ããã®æ··ä¹±ã¯æ²»çãåããããšã«æ¶æ¥µçã§ããããšãåå ã§ããããšè¿°ã¹ããç®ã«èŠããªãè «çãæ€æ»ãããªããŸãŸæŸçœ®ãããããããæ€æ»ãããªãã£ãç®èç å€ã远跡ãããªãã£ãPSAå€ãããã³èª¿æ»ãããªãã£ãå€§è žçç¶ã¯ãæšå®æ°å人ã®ãéå°ãæ»äº¡ãããããããããå»çã«ãããé å»¶ã¯ã容æãªæ²»çãšè€éãªæ²»çãé屿§çŸæ£ãšè»¢ç§»æ§çŸæ£ã®éããçããããçåã®å¯èœæ§ã«ææãªåœ±é¿ãåãŒãã
ååœãæ¯èŒãããšãããªãã®ã°ãã€ãããããäŸãã°ããã«ãŠã§ãŒãšãã¥ãŒãžãŒã©ã³ãã§ã¯ãããçºèŠã®æžå°å¹ ãå°ãããå埩ãéãã£ãããè±åœãšã¢ã€ã«ã©ã³ãã§ã¯ããã€ãã®ææšã§æçžŸãå£ã£ãŠãããåç«è ºããã§ã¯ãè±åœãäºæž¬çºççãšèгå¯çºççã®å·®ãæã倧ããã£ããåç ç©¶ã§çšããããæž¬å®å€ã¯ã10äžäººã»å¹Žåœããã®çäŸæ°ãã§ãããããã¯10äžäººã1幎é远跡ããå Žåã«äºæ³ãããããèšºææ°ãæå³ãããè±åœã®åç«è ºããçºççã¯10äžäººã»å¹Žåœãã164.9äŸãšäºæž¬ãããŠããã®ã«å¯Ÿãã2020幎ã«ã¯101.4äŸã§ãã£ããå¯Ÿç §çã«ãã«ãŠã§ãŒã¯164.1äŸãšäºæž¬ããŠããããå®éã«ã¯168.4äŸã§ãããæ°åã³ãããŠã€ã«ã¹ã®å¶éã«ããå·®ã¯ã»ãšãã©ãªãã£ãã
è±åœã®æ°åã¯ç¹ã«è¡æçã ãæ¬ æçã«é¢ããŠã¯ãååœã§ã¯åç«è ºããã§äºæž¬çäŸãšèгå¯çäŸã®éã«54%ã®å·®ãä¹³ããã§40%ã®å·®ãã¡ã©ããŒãã§40%ã®å·®ãçãããã¢ã€ã«ã©ã³ãã§ãåç«è ºããã§36%ãä¹³ããã§34%ãšå€§ããªæ¬ æãã¿ããããã«ããã§ã¯ã¡ã©ããŒãã§35%ã®æ¬ æãèšé²ãããã
2026幎2æã«JAMA Oncologyèªã«çºè¡šãããå¥ã®ç ç©¶ã§ã¯ããã³ãããã¯æä»£ã®æ··ä¹±ãããçåçã«åãŒã圱é¿ãããã«åŒ·èª¿ãããŠããã2020幎ããã³2021å¹Žã«æµžæœ€ãããšèšºæãããç±³åœã®æ£è 100äžäººè¶ ãè§£æãããšããã2015ïœ2019幎ã®ãã³ãããã¯åã®åŸåãšæ¯èŒããŠãããç¹ç°ç1幎çåçãäžè¯ã§ããããšãç ç©¶è ãã«ããèŠåºãããããããã®äœäžã¯ã蚺æãã1幎以å ã«ããé¢é£æ»ãæšå®17,390人å¢å ããããšã«ã€ãªããã2020幎ã«ã¯9,162人ã2021幎ã«ã¯8,228人ã§ãã£ãã
ç±³åœã®ç ç©¶ã¯ã7ãåœã®ã°ã«ãŒãå šäœã§èŠéããã蚺æã§ã¯ãªãçåã調æ»ãããã®ã§ãããããã©ã³ã»ããã»ãªã³ã³ããžãŒã®ç ç©¶çµæãçŽæ¥æ¡åŒµãããã®ã§ã¯ãããŸãããããããããã¯åããã¿ãŒã³ã®äžéšã§ããã¹ã¯ãªãŒãã³ã°ã蚺æãæ²»çãäžæãããããã害ã¯å¿ ãããããã«çŸããããã§ã¯ãããŸãããæ¬åœã®å®³ãç¥ãã«ã¯ãæ°ãæããæ°å¹ŽãããããšããããŸãã
Covidäžã®å»çæ¿çã¯ãCovidã«ããæ»äº¡ãäºé²ãããšãã1ã€ã®æ¬ã«ããåœãæ°ããããšãã§ããªããã®ããã«åžžã«è°è«ãããŠãããç é¢ãä¿è·ããææãæžããããæ²ç·ãå¹³åŠåããããããã®èšºæã«é¢ããæ°ããªç ç©¶ã¯ãä»ã®å¥åº·äžã®æžå¿µãäžå€ã«ããŠæ¶ããããã§ã¯ãªãããšããåœåå€ãã®äººã«ãšã£ãŠæããã§ãã£ãããšã瀺ããŠãããçã®ã³ã¹ãã¯å ¬åŒã®ç ç©¶ã«ãã£ãŠåŸã ã«æããã«ããã€ã€ãããããã§ã¯ã蚺æã®é ããæ²»çã®äžæãçç¶ã®èŠéããã·ã¹ãã ãžã®ä¿¡é Œã®åªå€±ãäœå人ãã®åœãäžå¿ èŠã«ç ç²ã«ãããšãããããªã蚌æ ãèŠãããã
å€ãã®äººããå®¶ã«ãããããšãçå£ã«èããããŠããŸãããå©ããæ±ããã¹ããšãã«ãããããããšã¯å±éºã§ãããšç¢ºä¿¡ããŠãããããäžè¬å»ãé¿ãã人ãããŸãããã¹ã¯ãªãŒãã³ã°ãŸãã¯å¥åº·èšºæã®æåŸ ã¯ç¡èŠãããç é¢ã¯ãCovidçäŸã«é¢ãããã®ã§ãªãéãã蚪åããã®ã¯å®å šã§ã¯ãªããšå®£äŒãããŸããããŸãããã³ãããã¯ã«å®å šã«çŠç¹ãåœãŠãã·ã¹ãã ã«ã¢ã¯ã»ã¹ã§ããªãã£ã人ãããŸããã
æ¿åºãä¿å¥åœå±ã¯çŸåšãCovidãäžå¯èœãªéžæè¢ãæç€ºãããšäž»åŒµããå¯èœæ§ããããããããããã¯åœŒããäŒèšã®åœ±é¿ãåããªãããã«ãããã®ã§ã¯ãªããã¡ã³ã¿ã«ãã«ã¹ããããå¿çŸæ£ããã®ä»ã®æ»å ã¯ãCovidãäžå¿çãªæ®µéã«ãªãã«ã€ããŠãèæ¯éé³ãšããŠæ±ãããã
ãããã£ãŠãLancet Oncologyèªã®ç ç©¶ã¯ãåãªãå»åŠè«æä»¥äžã®ãã®ãšããŠèªãã¹ãã§ãããããã¯ãã³ãããã¯ã»ã¬ããã³ã¹ã«é¢ããäºåŸåæã§ããã屿©å¯Ÿå¿ãããã«ãå¥åº·ãã®å®çŸ©ãçããäœæ°ã«æå®³ãäžããŠãããã瀺ããŠããããŸããã¬ãžãªãšã³ã¹å¯Ÿçããæ¥åžžçãªèšºæã厩å£ãããªãããå»çãµãŒãã¹å šäœã1ã€ã®ãçŸæ£ãã«åããèœåãæäŸãã¹ãã§ã¯ãªãçç±ãæããã«ããŠããã
2020幎ã«è¡æ¹äžæã«ãªã£ãã¬ã³æ£è ã¯ãéå»ã®æ°åã ãã§ã¯ãªããæ¬¡ã®ãç·æ¥äºæ ãã«å¯ŸããèŠåã ãéå»ã®å€§æµè¡ã¯çµãã£ããããããªãããæ²»çãåããããªãã£ãããšã®çµæã¯äŸç¶ãšããŠèšç®ãããŠãããããã2ã€ã®ç¹å®ã®ç ç©¶ã ãã§ãæ°åäººã®æ£è ããããŠäžçäžã§ããã«æ°çŸäžäººã®æ£è ã«ãšã£ãŠãããã¯ããŠã³ã®è²»çšã¯æ¯æ¥ã®Covidã®æ°å€ãæææ²ç·ã«ã¯å«ãŸããŠããªãã£ãããã®ä»£ããã«ãå®éã®è²»çšã¯ã圌ãã®åœãæãã«ã¯é ããã蚺æã§åŸã«èšé²ãããã